Danaher (NYSE:DHR) Now Covered by Scotiabank

Scotiabank began coverage on shares of Danaher (NYSE:DHR) in a report published on Monday morning, MarketBeat Ratings reports. The brokerage issued a sector perform rating and a $265.00 price target on the conglomerate’s stock.

Several other equities research analysts have also commented on the company. Wells Fargo & Company started coverage on Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Raymond James decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Stephens reissued an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Finally, TD Cowen upped their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $287.05.

Danaher Price Performance

NYSE:DHR opened at $229.16 on Monday. The firm has a market cap of $165.52 billion, a price-to-earnings ratio of 43.73, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83. Danaher has a 12-month low of $222.53 and a 12-month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company’s 50-day moving average is $243.07 and its two-hundred day moving average is $256.36.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.02 EPS. Research analysts expect that Danaher will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.47%. Danaher’s dividend payout ratio is presently 20.61%.

Hedge Funds Weigh In On Danaher

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. nVerses Capital LLC bought a new position in Danaher in the 2nd quarter valued at about $25,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC acquired a new position in shares of Danaher during the third quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in Danaher during the third quarter worth approximately $55,000. 79.05% of the stock is owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.